Difference between revisions of "Part:BBa K3346001:Design"
 
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
The sequences of the variable light chain Siltuximab fragment and murine constant light chain fragment were combined together in order to procure a chimeric monoclonal antibody using a murine constant chain. This allows for employment in our lateral flow assay, which uses an anti-mouse antibody at the control line. We also performed codon optimization for an E. coli chassis on the light chain sequences using Reverse Translate Software available on The Sequence Manipulation Site.
+
The sequences of the variable light chain Siltuximab fragment and murine constant light chain fragment were combined together in order to procure a chimeric monoclonal antibody using a murine constant chain. This allows for employment in our lateral flow assay, which uses an anti-mouse antibody at the control line. We also performed codon optimization for an E. coli chassis on the light chain sequences using Reverse Translate Software available on The Sequence Manipulation Suite.
  
  

Latest revision as of 21:26, 23 October 2020


Siltuximab Light Chain for IgG


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

The sequences of the variable light chain Siltuximab fragment and murine constant light chain fragment were combined together in order to procure a chimeric monoclonal antibody using a murine constant chain. This allows for employment in our lateral flow assay, which uses an anti-mouse antibody at the control line. We also performed codon optimization for an E. coli chassis on the light chain sequences using Reverse Translate Software available on The Sequence Manipulation Suite.


Source

The sequence for the variable portion of the light chain was obtained from the IMGT Monoclonal Antibody Database. Since this sequence is owned by Janssen Biotech, we recommend that any individuals who build this BioBrick first reach out to Janssen Biotech for authorization. The murine constant light chain sequence was widely available as published on the UniProt database.


References